c-myc in vasculoproliferative disease

Area of Science:

• Vascular biology
• Molecular medicine
• Biotechnology

Background:

• Antisense oligonucleotides (ASOs) can suppress smooth muscle cell (SMC) proliferation.
• Genes like c-myc and c-myb are crucial for cellular growth.

Purpose of the Study:

• To investigate how delivery kinetics of ASOs targeting c-myc and c-myb affect SMC growth in injured rat carotid arteries.
• To compare the efficacy of acute versus sustained ASO release from polymer-based delivery systems.

Main Methods:

• Two distinct ASOs for c-myc and c-myb were administered perivascularly to injured rat carotid arteries.
• ASOs were delivered using Pluronic gels (acute release) and ethylene vinyl acetate copolymer (EVAc) matrices (sustained release).
• In vitro and in vivo proliferation, mRNA levels, and protein expression were assessed.

Main Results:

• Acute release inhibited in vitro proliferation by ~55%, while sustained release inhibited it by ~45%.
• Both delivery systems inhibited intimal hyperplasia with c-myb ASOs.
• Only sustained EVAc release of c-myc ASOs effectively inhibited intimal hyperplasia; Pluronic release failed due to early suppression followed by loss of regulation.

Conclusions:

• The efficacy of ASOs in suppressing SMC proliferation in vivo is highly dependent on the kinetics of gene expression and oligonucleotide delivery.
• Sustained release systems, like EVAc, are crucial for long-term therapeutic effects, particularly for oncogenes like c-myc.
• Delivery system design significantly influences the therapeutic outcome of antisense oligonucleotide therapy in vascular injury models.